NCT07252232
Clinical Trial Detail

Contact

Missing content? – Request curation!

Request curation for specific Genes, Variants, or PubMed publications.

Have questions, comments, or suggestions? - Let us know!

Email us at : ckbsupport@genomenon.com

NCT ID NCT07252232
Title Study of Daraxonrasib (RMC-6236) in Patients With Resected Pancreatic Ductal Adenocarcinoma (PDAC) (RASolute 304)
Acronym RASolute 304
Recruitment Recruiting
Gender both
Phase Phase III
Variant Requirements No
Sponsors Revolution Medicines, Inc.
Indications
Therapies
Age Groups: adult | senior
Covered Countries USA

Facility Status City State Zip Country Details
Hartford Healthcare NOT_YET_RECRUITING Hartford Connecticut 06103 United States Details
Community Health Network RECRUITING Indianapolis Indiana 46250 United States Details
Saint Luke's Cancer Institute RECRUITING Kansas City Missouri 64111 United States Details
Taylor Cancer Research Center RECRUITING Maumee Ohio 43537 United States Details
Avera Cancer Institute RECRUITING Sioux Falls South Dakota 57105 United States Details
Virginia Cancer Specialists NOT_YET_RECRUITING Fairfax Virginia 22031 United States Details
Pan American Oncology Trials, LLC RECRUITING San Juan Puerto Rico 00909 Puerto Rico Details
*Shaded cells indicate that there was no data available from clinicaltrials.gov for the field